These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 34097244)

  • 21. Comparison of Characteristics Between Chinese Patients Taking Glucagon-like Peptide 1 Receptor Agonists and Insulin: A Cross-sectional Database Analysis.
    Wang K; Chen Y; Strizek A; Boye K; Gu L; Liu Y; Qu S
    Clin Ther; 2019 Oct; 41(10):2057-2065. PubMed ID: 31514971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus.
    Capel M; Ciudin A; Mareque M; Rodríguez-Rincón RM; Simón S; Oyagüez I
    Pharmacoecon Open; 2020 Jun; 4(2):277-286. PubMed ID: 31338828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Single-Center Experience of Using Liraglutide in Adolescents With Obesity +/- Type 2 Diabetes.
    Dauleh H; Pasha M; Gad H; Haris B; Petrovski G; Afyouni H; Khalifa A; Shehzad S; Amin R; Chirayath S; Mohamadsalih G; Mohammed S; Malik RA; Hussain K
    Cureus; 2024 Apr; 16(4):e58720. PubMed ID: 38779269
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan.
    Gelhorn HL; Bacci ED; Poon JL; Boye KS; Suzuki S; Babineaux SM
    Patient Prefer Adherence; 2016; 10():1337-48. PubMed ID: 27524889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Effectiveness of Liraglutide in Association with Patients' Baseline Characteristics in Real-Life Setting in Croatia: An Observational, Retrospective, Multicenter Study.
    Berkovic MC; Bilic-Curcic I; Herman Mahecic D; Gradiser M; Grgurevic M; Bozek T
    Diabetes Ther; 2017 Dec; 8(6):1297-1308. PubMed ID: 29076038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Generalizability of the Results of Cardiovascular Outcome Trials of Glucagon-Like Peptide 1 Receptor Agonists in Chinese Patients with Type 2 Diabetes Mellitus.
    Cai X; Ji L
    Diabetes Ther; 2021 Jul; 12(7):1861-1870. PubMed ID: 34047959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Real-World Observational Study Evaluating the Probability of Glycemic Control with Basal Insulin or Glucagon-Like Peptide-1 Receptor Agonist in Japanese Patients with Type 2 Diabetes.
    Baxter M; Morimoto Y; Tamiwa M; Hattori M; Peng XV; Lubwama R; Maegawa H
    Diabetes Ther; 2020 Jul; 11(7):1481-1496. PubMed ID: 32445125
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.
    Patel H; Munir K; Sutherland S; Karanikas CA; Konig M
    Diabetes Ther; 2019 Dec; 10(6):2321-2330. PubMed ID: 31605302
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Efficacy of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist, Dulaglutide, on Metabolic Parameters in Japanese Patients with Type 2 Diabetes: A Retrospective Longitudinal Study.
    Katsuyama H; Hakoshima M; Umeyama S; Iida S; Adachi H; Yanai H
    Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective.
    Chuang LH; Verheggen BG; Charokopou M; Gibson D; Grandy S; Kartman B
    J Med Econ; 2016 Dec; 19(12):1127-1134. PubMed ID: 27310712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.
    Barrett A; Debackere N; Ribeiro A; Keapoletswe K; Zingel R; Coles B
    Adv Ther; 2023 Aug; 40(8):3446-3464. PubMed ID: 37286889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Retrospective Observational Study Examining the Generalizability of Glucagon-Like Peptide 1 Receptor Agonist Cardiovascular Outcome Trials to the Real-World Population with Type 2 Diabetes in Spain: The REPRESENT Study.
    Romera I; Artime E; Ihle K; Díaz-Cerezo S; Rubio de-Santos M; de Prado A; Cebrián-Cuenca A; Conget I
    Adv Ther; 2022 Aug; 39(8):3589-3601. PubMed ID: 35689162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
    Urquhart S; Willis S
    JAAPA; 2020 Aug; 33(8):19-30. PubMed ID: 32740122
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of Semaglutide Versus Dulaglutide on Epicardial Fat Thickness in Subjects with Type 2 Diabetes and Obesity.
    Iacobellis G; Villasante Fricke AC
    J Endocr Soc; 2020 Apr; 4(4):bvz042. PubMed ID: 32190806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-acting GLP-1 receptor agonists: Findings and implications of cardiovascular outcomes trials.
    Urquhart S; Willis S
    JAAPA; 2020 Aug; 33(S8 Suppl 1):19-30. PubMed ID: 32756221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of Liraglutide and Lixisenatide in the Treatment of Type 2 Diabetes: Real-World Evidence from The Health Improvement Network (THIN) Database in the United Kingdom.
    Feher M; Vega-Hernandez G; Mocevic E; Buysse B; Myland M; Power GS; Nystrup Husemoen LL; Kim J; Witte DR
    Diabetes Ther; 2017 Apr; 8(2):417-431. PubMed ID: 28281244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
    Hoog M; Maldonado JM; Wangia-Dixon R; Halpern R; Buysman E; Gremel GW; Huang A; Konig M
    Diabetes Ther; 2024 Apr; 15(4):855-867. PubMed ID: 38427164
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice.
    Lee J; Cho YK; Kim HS; Jung CH; Park JY; Lee WJ
    Diabetes Metab Syndr Obes; 2019; 12():2745-2753. PubMed ID: 31920354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Real-world effectiveness, adherence and persistence among patients with type 2 diabetes mellitus initiating dulaglutide treatment.
    Mody R; Grabner M; Yu M; Turner R; Kwan AYM; York W; Fernández Landó L
    Curr Med Res Opin; 2018 Jun; 34(6):995-1003. PubMed ID: 29271258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.